BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Yang YX, Hennessy S, Propert K, Hwang WT, Sedarat A, Lewis JD. Chronic proton pump inhibitor therapy and the risk of colorectal cancer. Gastroenterology. 2007;133:748-754. [PMID: 17678926 DOI: 10.1053/j.gastro.2007.06.022] [Cited by in Crossref: 84] [Cited by in F6Publishing: 77] [Article Influence: 5.6] [Reference Citation Analysis]
Number Citing Articles
1 Xiong J, Wang Y, Xu W, Liu Z, Wang H, Zhang Z, Han Y, Yin C, Cao S, Yang Z, Su T, Wei J, Chen G, Jin L. Proton pump inhibitors and odds of cholangiocarcinoma: A retrospective case‐control study. Liver Int 2020;40:2848-57. [DOI: 10.1111/liv.14663] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Kuiper JG, Herk‐sukel MPP, Lemmens VEPP, Kuipers EJ, Herings RMC. Proton pump inhibitors are not associated with an increased risk of colorectal cancer. GastroHep 2020;2:165-70. [DOI: 10.1002/ygh2.409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
3 Graham DY, Genta RM. Long-term proton pump inhibitor use and gastrointestinal cancer. Curr Gastroenterol Rep 2008;10:543-7. [PMID: 19006608 DOI: 10.1007/s11894-008-0100-1] [Cited by in Crossref: 38] [Cited by in F6Publishing: 34] [Article Influence: 2.9] [Reference Citation Analysis]
4 Bruno G, Zaccari P, Rocco G, Scalese G, Panetta C, Porowska B, Pontone S, Severi C. Proton pump inhibitors and dysbiosis: Current knowledge and aspects to be clarified. World J Gastroenterol 2019; 25(22): 2706-2719 [PMID: 31235994 DOI: 10.3748/wjg.v25.i22.2706] [Cited by in CrossRef: 55] [Cited by in F6Publishing: 42] [Article Influence: 18.3] [Reference Citation Analysis]
5 Hwang IC, Chang J, Park SM. Emerging hazard effects of proton pump inhibitor on the risk of colorectal cancer in low-risk populations: A Korean nationwide prospective cohort study. PLoS One 2017;12:e0189114. [PMID: 29216279 DOI: 10.1371/journal.pone.0189114] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 2.2] [Reference Citation Analysis]
6 Morton M, Prendergast C, Barrett TD. Targeting gastrin for the treatment of gastric acid related disorders and pancreatic cancer. Trends Pharmacol Sci. 2011;32:201-205. [PMID: 21397342 DOI: 10.1016/j.tips.2011.02.003] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
7 Islam MM, Poly TN, Walther BA, Dubey NK, Anggraini Ningrum DN, Shabbir SA, Jack Li YC. Adverse outcomes of long-term use of proton pump inhibitors: A systematic review and meta-analysis. Eur J Gastroenterol Hepatol. 2018;30:1395-1405. [PMID: 30028775 DOI: 10.1097/meg.0000000000001198] [Cited by in Crossref: 36] [Cited by in F6Publishing: 14] [Article Influence: 12.0] [Reference Citation Analysis]
8 Shi S, Klotz U. Proton pump inhibitors: an update of their clinical use and pharmacokinetics. Eur J Clin Pharmacol. 2008;64:935-951. [PMID: 18679668 DOI: 10.1007/s00228-008-0538-y] [Cited by in Crossref: 204] [Cited by in F6Publishing: 188] [Article Influence: 14.6] [Reference Citation Analysis]
9 Ma T, Wu M, Jia S, Yang L. Proton pump inhibitors and the risk of colorectal cancer: a systematic review and meta-analysis of observational studies. Int J Colorectal Dis 2020;35:2157-69. [DOI: 10.1007/s00384-020-03717-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
10 Smelick GS, Heffron TP, Chu L, Dean B, West DA, Duvall SL, Lum BL, Budha N, Holden SN, Benet LZ, Frymoyer A, Dresser MJ, Ware JA. Prevalence of acid-reducing agents (ARA) in cancer populations and ARA drug-drug interaction potential for molecular targeted agents in clinical development. Mol Pharm 2013;10:4055-62. [PMID: 24044612 DOI: 10.1021/mp400403s] [Cited by in Crossref: 87] [Cited by in F6Publishing: 78] [Article Influence: 9.7] [Reference Citation Analysis]
11 Patel A, Spychalski P, Antoszewska M, Regula J, Kobiela J. Proton pump inhibitors and colorectal cancer: A systematic review. World J Gastroenterol 2021; 27(44): 7716-7733 [PMID: 34908809 DOI: 10.3748/wjg.v27.i44.7716] [Reference Citation Analysis]
12 Chubak J, Boudreau DM, Rulyak SJ, Mandelson MT. Colorectal cancer risk in relation to use of acid suppressive medications. Pharmacoepidemiol Drug Saf 2009;18:540-4. [PMID: 19367565 DOI: 10.1002/pds.1749] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 1.4] [Reference Citation Analysis]
13 Zhang W, Wu J, Atkinson SN. Effects of dexlansoprazole MR, a novel dual delayed release formulation of a proton pump inhibitor, on plasma gastrin levels in healthy subjects. J Clin Pharmacol 2009;49:444-54. [PMID: 19318694 DOI: 10.1177/0091270008330155] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.7] [Reference Citation Analysis]
14 Dacha S, Razvi M, Massaad J, Cai Q, Wehbi M. Hypergastrinemia. Gastroenterol Rep (Oxf). 2015;3:201-208. [PMID: 25698559 DOI: 10.1093/gastro/gov004] [Cited by in Crossref: 32] [Cited by in F6Publishing: 30] [Article Influence: 4.6] [Reference Citation Analysis]
15 Mims JW. The impact of extra-esophageal reflux upon diseases of the upper respiratory tract. Curr Opin Otolaryngol Head Neck Surg 2008;16:242-6. [PMID: 18475079 DOI: 10.1097/MOO.0b013e3282fdc3d6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Mejia A, Kraft WK. Acid peptic diseases: pharmacological approach to treatment. Expert Rev Clin Pharmacol. 2009;2:295-314. [PMID: 21822447 DOI: 10.1586/ecp.09.8] [Cited by in Crossref: 53] [Cited by in F6Publishing: 46] [Article Influence: 6.6] [Reference Citation Analysis]
17 Kinoshita Y, Ishimura N, Ishihara S. Advantages and Disadvantages of Long-term Proton Pump Inhibitor Use. J Neurogastroenterol Motil 2018;24:182-96. [PMID: 29605975 DOI: 10.5056/jnm18001] [Cited by in Crossref: 76] [Cited by in F6Publishing: 55] [Article Influence: 19.0] [Reference Citation Analysis]
18 Haastrup PF, Jarbøl DE, Thompson W, Hansen JM, Søndergaard J, Rasmussen S. When does proton pump inhibitor treatment become long term? A scoping review. BMJ Open Gastroenterol 2021;8:e000563. [PMID: 33589415 DOI: 10.1136/bmjgast-2020-000563] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Joo MK, Park JJ, Chun HJ. Additional Benefits of Routine Drugs on Gastrointestinal Cancer: Statins, Metformin, and Proton Pump Inhibitors. Dig Dis 2018;36:1-14. [PMID: 28881340 DOI: 10.1159/000480149] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 3.8] [Reference Citation Analysis]
20 Koulouridi A, Messaritakis I, Gouvas N, Tsiaoussis J, Souglakos J. Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation-A Special Reference to Colorectal Cancer. Cancers (Basel) 2020;13:E43. [PMID: 33375686 DOI: 10.3390/cancers13010043] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
21 Schneider JL, Kolitsopoulos F, Corley DA. Risk of gastric cancer, gastrointestinal cancers and other cancers: A comparison of treatment with pantoprazole and other proton pump inhibitors. Aliment Pharmacol Ther. 2016;43:73-82. [PMID: 26541643 DOI: 10.1111/apt.13450] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 2.7] [Reference Citation Analysis]
22 Ahn JS, Park SM, Eom CS, Kim S, Myung SK. Use of Proton Pump Inhibitor and Risk of Colorectal Cancer: A Meta-analysis of Observational Studies. Korean J Fam Med 2012;33:272-9. [PMID: 23115701 DOI: 10.4082/kjfm.2012.33.5.272] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 1.9] [Reference Citation Analysis]
23 Vaezi MF, Yang YX, Howden CW. Complications of Proton Pump Inhibitor Therapy. Gastroenterology. 2017;153:35-48. [PMID: 28528705 DOI: 10.1053/j.gastro.2017.04.047] [Cited by in Crossref: 198] [Cited by in F6Publishing: 146] [Article Influence: 39.6] [Reference Citation Analysis]
24 Yang YX, Metz DC. Safety of proton pump inhibitor exposure. Gastroenterology. 2010;139:1115-1127. [PMID: 20727892 DOI: 10.1053/j.gastro.2010.08.023] [Cited by in Crossref: 137] [Cited by in F6Publishing: 119] [Article Influence: 11.4] [Reference Citation Analysis]
25 Lee L, Ramos-Alvarez I, Ito T, Jensen RT. Insights into Effects/Risks of Chronic Hypergastrinemia and Lifelong PPI Treatment in Man Based on Studies of Patients with Zollinger-Ellison Syndrome. Int J Mol Sci 2019;20:E5128. [PMID: 31623145 DOI: 10.3390/ijms20205128] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 3.7] [Reference Citation Analysis]
26 Bradley MC, Hughes CM, Cantwell MM, Murray LJ. Statins and pancreatic cancer risk: a nested case-control study. Cancer Causes Control. 2010;21:2093-2100. [PMID: 20697797 DOI: 10.1007/s10552-010-9628-0] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 1.7] [Reference Citation Analysis]
27 Freston JW, Hisada M, Peura DA, Haber MM, Kovacs TO, Atkinson S, Hunt B. The clinical safety of long-term lansoprazole for the maintenance of healed erosive oesophagitis. Alimentary Pharmacology & Therapeutics 2009;29:1249-60. [DOI: 10.1111/j.1365-2036.2009.03998.x] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
28 Wong GG, Ha V, Chu MP, Dersch-Mills D, Ghosh S, Chambers CR, Sawyer MB. Effects of Proton Pump Inhibitors on FOLFOX and CapeOx Regimens in Colorectal Cancer. Clin Colorectal Cancer 2019;18:72-9. [PMID: 30551953 DOI: 10.1016/j.clcc.2018.11.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 18] [Article Influence: 4.3] [Reference Citation Analysis]
29 Schubert ML, Peura DA. Control of gastric acid secretion in health and disease. Gastroenterology. 2008;134:1842-1860. [PMID: 18474247 DOI: 10.1053/j.gastro.2008.05.021] [Cited by in Crossref: 269] [Cited by in F6Publishing: 222] [Article Influence: 19.2] [Reference Citation Analysis]
30 Babic A, Zhang X, Morales-Oyarvide V, Yuan C, Khalaf N, Khalili H, Lochhead P, Chan AT, Ogino S, Wolpin BM, Wu K, Fuchs CS, Giovannucci EL, Stampfer MJ, Ng K. Acid-suppressive medications and risk of colorectal cancer: results from three large prospective cohort studies. Br J Cancer 2020;123:844-51. [PMID: 32541871 DOI: 10.1038/s41416-020-0939-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
31 Yee YK, Tan VP, Chan P, Hung IF, Pang R, Wong BC. Epidemiology of colorectal cancer in Asia. J Gastroenterol Hepatol. 2009;24:1810-1816. [PMID: 20002940 DOI: 10.1111/j.1440-1746.2009.06138.x] [Cited by in Crossref: 54] [Cited by in F6Publishing: 38] [Article Influence: 4.5] [Reference Citation Analysis]
32 Kearns MD, Boursi B, Yang YX. Proton pump inhibitors on pancreatic cancer risk and survival. Cancer Epidemiol 2017;46:80-4. [PMID: 28056391 DOI: 10.1016/j.canep.2016.12.006] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 6.0] [Reference Citation Analysis]
33 Devault KR, Talley NJ. Insights into the future of gastric acid suppression. Nat Rev Gastroenterol Hepatol 2009;6:524-32. [DOI: 10.1038/nrgastro.2009.125] [Cited by in Crossref: 47] [Cited by in F6Publishing: 40] [Article Influence: 3.6] [Reference Citation Analysis]
34 Abrahami D, McDonald EG, Schnitzer ME, Barkun AN, Suissa S, Azoulay L. Proton pump inhibitors and risk of colorectal cancer. Gut 2021:gutjnl-2021-325096. [PMID: 34210775 DOI: 10.1136/gutjnl-2021-325096] [Reference Citation Analysis]
35 Ogdie A, Langan SM, Parkinson J, Dattani H, Kostev K, Gelfand JM. Medical Record Databases. In: Strom BL, Kimmel SE, Hennessy S, editors. Pharmacoepidemiology. Oxford: Wiley-Blackwell; 2012. pp. 224-43. [DOI: 10.1002/9781119959946.ch15] [Cited by in Crossref: 23] [Cited by in F6Publishing: 12] [Article Influence: 2.3] [Reference Citation Analysis]
36 de Jonge PJ, van Blankenstein M, Looman CW, Casparie MK, Meijer GA, Kuipers EJ. Risk of colorectal cancer in patients with Barrett's esophagus: A Dutch population-based study. Am J Gastroenterol 2010;105:77-83. [PMID: 19724268 DOI: 10.1038/ajg.2009.503] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
37 Wang JS, Varro A, Lightdale CJ, Lertkowit N, Slack KN, Fingerhood ML, Tsai WY, Wang TC, Abrams JA. Elevated serum gastrin is associated with a history of advanced neoplasia in Barrett's esophagus. Am J Gastroenterol 2010;105:1039-45. [PMID: 19904251 DOI: 10.1038/ajg.2009.629] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 2.5] [Reference Citation Analysis]
38 Jensen RT, Norton JA. Endocrine Tumors of the Pancreas and Gastrointestinal Tract. Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Elsevier; 2010. pp. 491-522.e7. [DOI: 10.1016/b978-1-4160-6189-2.00032-9] [Cited by in Crossref: 6] [Article Influence: 0.5] [Reference Citation Analysis]
39 Shiratori Y, Ikeya T, Ishii N, Yamamoto K, Honda T, Hasatani K, Yoshida N, Nishida T, Sumiyoshi T, Kiyotoki S, Arai M, Niikura R. Association between the chronic use of gastric acid suppressants and high-risk colorectal polyps. JGH Open 2021;5:371-6. [PMID: 33732884 DOI: 10.1002/jgh3.12503] [Reference Citation Analysis]
40 Paterson AC, Macrae FA, Pizzey C, Baldwin GS, Shulkes A. Circulating gastrin concentrations in patients at increased risk of developing colorectal carcinoma: Gastrins and colorectal carcinoma risk. J Gastroenterol Hepatol 2014;29:480-6. [DOI: 10.1111/jgh.12417] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
41 Kovac S, Xiao L, Shulkes A, Patel O, Baldwin GS. Gastrin increases its own synthesis in gastrointestinal cancer cells via the CCK2 receptor. FEBS Lett. 2010;584:4413-4418. [PMID: 20932834 DOI: 10.1016/j.febslet.2010.09.046] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
42 Freeman HJ. Proton pump inhibitors and an emerging epidemic of gastric fundic gland polyposis. World J Gastroenterol 2008; 14(9): 1318-1320 [PMID: 18322941 DOI: 10.3748/wjg.14.1318] [Cited by in CrossRef: 33] [Cited by in F6Publishing: 31] [Article Influence: 2.4] [Reference Citation Analysis]
43 Chien LN, Huang YJ, Shao YH, Chang CJ, Chuang MT, Chiou HY, Yen Y. Proton pump inhibitors and risk of periampullary cancers--A nested case-control study. Int J Cancer. 2016;138:1401-1409. [PMID: 26488896 DOI: 10.1002/ijc.29896] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 2.6] [Reference Citation Analysis]
44 Roulet L, Vernaz N, Giostra E, Gasche Y, Desmeules J. [Adverse effects of proton pump inhibitors: should we worry about long-term exposure?]. Rev Med Interne 2012;33:439-45. [PMID: 22284952 DOI: 10.1016/j.revmed.2011.12.011] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
45 Teixeira MZ. Rebound acid hypersecretion after withdrawal of gastric acid suppressing drugs: new evidence of similitude. Homeopathy. 2011;100:148-156. [PMID: 21784332 DOI: 10.1016/j.homp.2011.05.003] [Cited by in Crossref: 12] [Cited by in F6Publishing: 7] [Article Influence: 1.1] [Reference Citation Analysis]
46 Song HJ, Jeon N, Squires P. The association between acid-suppressive agent use and the risk of cancer: a systematic review and meta-analysis. Eur J Clin Pharmacol 2020;76:1437-56. [PMID: 32548678 DOI: 10.1007/s00228-020-02927-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
47 Poulsen AH, Christensen S, McLaughlin JK, Thomsen RW, Sørensen HT, Olsen JH, Friis S. Proton pump inhibitors and risk of gastric cancer: a population-based cohort study. Br J Cancer. 2009;100:1503-1507. [PMID: 19352380 DOI: 10.1038/sj.bjc.6605024] [Cited by in Crossref: 82] [Cited by in F6Publishing: 74] [Article Influence: 6.3] [Reference Citation Analysis]
48 Graham C, Orr C, Bricks CS, Hopman WM, Hammad N, Ramjeesingh R. A retrospective analysis of the role of proton pump inhibitors in colorectal cancer disease survival. Curr Oncol 2016;23:e583-8. [PMID: 28050148 DOI: 10.3747/co.23.3204] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
49 Reimer C. Safety of long-term PPI therapy. Best Practice & Research Clinical Gastroenterology 2013;27:443-54. [DOI: 10.1016/j.bpg.2013.06.001] [Cited by in Crossref: 59] [Cited by in F6Publishing: 51] [Article Influence: 6.6] [Reference Citation Analysis]
50 Laiyemo AO, Kamangar F, Marcus PM, Taylor PR, Virtamo J, Albanes D, Stolzenberg-Solomon RZ. Atrophic gastritis and the risk of incident colorectal cancer. Cancer Causes Control 2010;21:163-70. [PMID: 19838812 DOI: 10.1007/s10552-009-9446-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 0.5] [Reference Citation Analysis]
51 Rakesh TP. Proton pump inhibitors: use, misuse and concerns about long-term therapy. Clin J Gastroenterol 2011;4:53-9. [DOI: 10.1007/s12328-011-0208-y] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
52 Hálfdánarson ÓÖ, Fall K, Ogmundsdottir MH, Lund SH, Steingrímsson E, Ogmundsdottir HM, Zoega H. Proton pump inhibitor use and risk of breast cancer, prostate cancer, and malignant melanoma: An Icelandic population‐based case‐control study. Pharmacoepidemiol Drug Saf 2019;28:471-8. [DOI: 10.1002/pds.4702] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
53 Heidelbaugh JJ, Metz DC, Yang YX. Proton pump inhibitors: are they overutilised in clinical practice and do they pose significant risk? Int J Clin Pract. 2012;66:582-591. [PMID: 22607510 DOI: 10.1111/j.1742-1241.2012.02921.x] [Cited by in Crossref: 27] [Cited by in F6Publishing: 20] [Article Influence: 2.7] [Reference Citation Analysis]
54 Lei WY, Wang JH, Yi CH, Liu TT, Hung JS, Wong MW, Bair MJ, Vaezi MF, Orr WC, Chen CL. Association between use of proton pump inhibitors and colorectal cancer: A nationwide population-based study. Clin Res Hepatol Gastroenterol 2021;45:101397. [PMID: 32224118 DOI: 10.1016/j.clinre.2020.02.017] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 5.0] [Reference Citation Analysis]
55 von Rahden BH, Scheurlen M, Filser J, Stein HJ, Germer CT. [Newly recognized side-effects of proton pump inhibitors. Arguments in favour of fundoplication for GERD?]. Chirurg. 2012;83:38-44. [PMID: 21909830 DOI: 10.1007/s00104-011-2173-x] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
56 Eusebi LH, Rabitti S, Artesiani ML, Gelli D, Montagnani M, Zagari RM, Bazzoli F. Proton pump inhibitors: Risks of long-term use: Proton pump inhibitors. Journal of Gastroenterology and Hepatology 2017;32:1295-302. [DOI: 10.1111/jgh.13737] [Cited by in Crossref: 77] [Cited by in F6Publishing: 60] [Article Influence: 15.4] [Reference Citation Analysis]
57 Amano Y, Nakahara R, Yuki T, Murakami D, Ujihara T, Tomoyuki I, Sagami R, Suehiro S, Katsuyama Y, Hayasaka K, Harada H, Tada Y, Miyaoka Y, Fujishiro H. Relationship between Barrett's esophagus and colonic diseases: a role for colonoscopy in Barrett's surveillance. J Gastroenterol 2019;54:984-93. [PMID: 31240437 DOI: 10.1007/s00535-019-01600-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
58 Kao WY, Su CW, Chia-Hui Tan E, Lee PC, Chen PH, Tang JH, Huang YH, Huo TI, Chang CC, Hou MC, Lin HC, Wu JC. Proton Pump Inhibitors and Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B or C. Hepatology 2019;69:1151-64. [PMID: 30175498 DOI: 10.1002/hep.30247] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 3.7] [Reference Citation Analysis]
59 Triadafilopoulos G, Roorda AK, Akiyama J. Indications and safety of proton pump inhibitor drug use in patients with cancer. Expert Opin Drug Saf. 2013;12:659-672. [PMID: 23647006 DOI: 10.1517/14740338.2013.797961] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.4] [Reference Citation Analysis]
60 Bradley MC, Murray LJ, Cantwell MM, Hughes CM. Proton pump inhibitors and histamine-2-receptor antagonists and pancreatic cancer risk: a nested case-control study. Br J Cancer 2012;106:233-9. [PMID: 22108522 DOI: 10.1038/bjc.2011.511] [Cited by in Crossref: 27] [Cited by in F6Publishing: 28] [Article Influence: 2.5] [Reference Citation Analysis]
61 Wang X, Liu Q, Halfdanarson ÓÖ, Zoega H, Sadr-Azodi O, Engstrand L, Fall K, Brusselaers N. Proton pump inhibitors and survival in patients with colorectal cancer: a Swedish population-based cohort study. Br J Cancer 2021. [PMID: 34253872 DOI: 10.1038/s41416-021-01480-0] [Reference Citation Analysis]
62 van Soest EM, van Rossum LG, Dieleman JP, van Oijen MG, Siersema PD, Sturkenboom MC, Kuipers EJ. Proton pump inhibitors and the risk of colorectal cancer. Am J Gastroenterol. 2008;103:966-973. [PMID: 18070237 DOI: 10.1111/j.1572-0241.2007.01665.x] [Cited by in Crossref: 48] [Cited by in F6Publishing: 47] [Article Influence: 3.2] [Reference Citation Analysis]
63 Coté GA, Howden CW. Potential adverse effects of proton pump inhibitors. Curr Gastroenterol Rep 2008;10:208-14. [DOI: 10.1007/s11894-008-0045-4] [Cited by in Crossref: 43] [Cited by in F6Publishing: 36] [Article Influence: 3.1] [Reference Citation Analysis]
64 Hsu W, Wu I, Kuo C, Su Y, Lu C, Kuo F, Jan C, Wang W, Wu D, Yu F. Influence of Proton Pump Inhibitor Use in Gastrointestinal Polyps. The Kaohsiung Journal of Medical Sciences 2010;26:76-83. [DOI: 10.1016/s1607-551x(10)70011-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
65 Nealis TB, Howden CW. Is there a dark side to long-term proton pump inhibitor therapy? Am J Ther. 2008;15:536-542. [PMID: 19127138 DOI: 10.1097/mjt.0b013e31817149bf] [Cited by in Crossref: 25] [Cited by in F6Publishing: 10] [Article Influence: 1.9] [Reference Citation Analysis]
66 Oberg K. Pancreatic endocrine tumors. Semin Oncol. 2010;37:594-618. [PMID: 21167379 DOI: 10.1053/j.seminoncol.2010.10.014] [Cited by in Crossref: 118] [Cited by in F6Publishing: 96] [Article Influence: 10.7] [Reference Citation Analysis]
67 Charlton R, Snowball J, Bloomfield K, de Vries C. Colorectal cancer incidence on the General Practice Research Database. Pharmacoepidemiol Drug Saf 2012;21:775-83. [PMID: 22383247 DOI: 10.1002/pds.3236] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
68 Boursi B, Mamtani R, Haynes K, Yang Y. Pernicious anemia and colorectal cancer risk – A nested case–control study. Digestive and Liver Disease 2016;48:1386-90. [DOI: 10.1016/j.dld.2016.07.011] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
69 Talley NJ. Risks of proton‐pump inhibitors: what every doctor should know. Medical Journal of Australia 2009;190:109-10. [DOI: 10.5694/j.1326-5377.2009.tb02305.x] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
70 Zeng R, Cheng Y, Luo D, Wang J, Yang J, Jiang L, Zhuo Z, Guo K, Wu H, Leung FW, Sha W, Chen H. Comprehensive analysis of proton pump inhibitors and risk of digestive tract cancers. Eur J Cancer 2021;156:190-201. [PMID: 34481369 DOI: 10.1016/j.ejca.2021.07.030] [Reference Citation Analysis]
71 Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. Dig Dis Sci. 2011;56:931-950. [PMID: 21365243 DOI: 10.1007/s10620-010-1560-3] [Cited by in Crossref: 187] [Cited by in F6Publishing: 167] [Article Influence: 17.0] [Reference Citation Analysis]
72 Robertson DJ, Sandler RS, Ahnen DJ, Greenberg ER, Mott LA, Cole BF, Baron JA. Gastrin, Helicobacter pylori, and colorectal adenomas. Clin Gastroenterol Hepatol. 2009;7:163-167. [PMID: 18929688 DOI: 10.1016/j.cgh.2008.09.006] [Cited by in Crossref: 26] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
73 Makar GA, Holmes JH, Yang YX. Angiotensin-converting enzyme inhibitor therapy and colorectal cancer risk. J Natl Cancer Inst 2014;106:djt374. [PMID: 24431411 DOI: 10.1093/jnci/djt374] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 5.8] [Reference Citation Analysis]
74 Raoul JL, Edeline J, Gilabert M, Senellart H, Frenel JS. [Proton pump inhibitors and cancers: A hazardous association?]. Bull Cancer 2020;107:458-64. [PMID: 32057465 DOI: 10.1016/j.bulcan.2019.12.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Subramaniam D, Ramalingam S, May R, Dieckgraefe BK, Berg DE, Pothoulakis C, Houchen CW, Wang TC, Anant S. Gastrin-mediated interleukin-8 and cyclooxygenase-2 gene expression: differential transcriptional and posttranscriptional mechanisms. Gastroenterology. 2008;134:1070-1082. [PMID: 18395088 DOI: 10.1053/j.gastro.2008.01.040] [Cited by in Crossref: 40] [Cited by in F6Publishing: 46] [Article Influence: 2.9] [Reference Citation Analysis]
76 Han YM, Hahm KB, Park JM, Hong SP, Kim EH. Paradoxically augmented anti-tumorigenic action of proton pump inhibitor and GastrininAPCMin/+ intestinal polyposis model. Neoplasia 2014;16:73-83. [PMID: 24563620 DOI: 10.1593/neo.131510] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 2.5] [Reference Citation Analysis]
77 Bradley MC, Hughes CM, Cantwell MM, Napolitano G, Murray LJ. Non-steroidal anti-inflammatory drugs and pancreatic cancer risk: a nested case-control study. Br J Cancer. 2010;102:1415-1421. [PMID: 20372155 DOI: 10.1038/sj.bjc.6605636] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.7] [Reference Citation Analysis]